S&P 500   3,113.51 (+0.55%)
DOW   27,919.89 (+0.50%)
QQQ   202.56 (+0.56%)
BABA   185.00 (+1.20%)
GE   11.50 (+1.86%)
T   39.26 (+0.80%)
ACB   2.89 (-12.16%)
F   8.96 (+1.93%)
DIS   144.96 (-1.49%)
S&P 500   3,113.51 (+0.55%)
DOW   27,919.89 (+0.50%)
QQQ   202.56 (+0.56%)
BABA   185.00 (+1.20%)
GE   11.50 (+1.86%)
T   39.26 (+0.80%)
ACB   2.89 (-12.16%)
F   8.96 (+1.93%)
DIS   144.96 (-1.49%)
S&P 500   3,113.51 (+0.55%)
DOW   27,919.89 (+0.50%)
QQQ   202.56 (+0.56%)
BABA   185.00 (+1.20%)
GE   11.50 (+1.86%)
T   39.26 (+0.80%)
ACB   2.89 (-12.16%)
F   8.96 (+1.93%)
DIS   144.96 (-1.49%)
S&P 500   3,113.51 (+0.55%)
DOW   27,919.89 (+0.50%)
QQQ   202.56 (+0.56%)
BABA   185.00 (+1.20%)
GE   11.50 (+1.86%)
T   39.26 (+0.80%)
ACB   2.89 (-12.16%)
F   8.96 (+1.93%)
DIS   144.96 (-1.49%)
Log in

Novavax Stock Price, Forecast & Analysis (NASDAQ:NVAX)

$4.15
-0.07 (-1.66 %)
(As of 11/15/2019 01:50 PM ET)
Today's Range
$4.03
Now: $4.15
$4.22
50-Day Range
$4.14
MA: $4.70
$6.26
52-Week Range
$4.01
Now: $4.15
$51.60
Volume6,610 shs
Average Volume577,613 shs
Market Capitalization$110.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.9
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.29 million
Book Value($7.14) per share

Profitability

Net Income$-184,750,000.00
Net Margins-940.32%

Miscellaneous

Employees373
Market Cap$110.31 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.


Novavax (NASDAQ:NVAX) Frequently Asked Questions

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

When did Novavax's stock split? How did Novavax's stock split work?

Novavax shares reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.98) by $0.24. The biopharmaceutical company had revenue of $2.51 million for the quarter, compared to the consensus estimate of $4.40 million. During the same period in the previous year, the business posted ($2.40) earnings per share. View Novavax's Earnings History.

When is Novavax's next earnings date?

Novavax is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Novavax.

What price target have analysts set for NVAX?

10 Wall Street analysts have issued twelve-month target prices for Novavax's stock. Their forecasts range from $7.00 to $90.00. On average, they expect Novavax's stock price to reach $33.83 in the next twelve months. This suggests a possible upside of 715.3% from the stock's current price. View Analyst Price Targets for Novavax.

What is the consensus analysts' recommendation for Novavax?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novavax.

What are Wall Street analysts saying about Novavax stock?

Here are some recent quotes from research analysts about Novavax stock:
  • 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (10/25/2019)
  • 2. HC Wainwright analysts commented, "We derived our price target of $12 using DCF methodology with a 30% discount rate, 2% terminal growth rate, and a clinical program probability-of-success of 72%. Risks to our investment thesis include failure of clinical trials, regulatory requirements for additional clinical studies, unproven commercialization strategy, failure of products to show sufficient differentiation in targeted therapeutic indications, patent expiry or invalidation, and potential to raise additional funds under poor market conditions." (7/1/2019)
  • 3. Cantor Fitzgerald analysts commented, "Our Neutral rating for NVAX stock is based on the uncertainty as to how the company’s technologies will be applied in the successful development of proprietary vaccines and where or how NVAX will access the capital necessary to realize that potential. Positive data for vaccine candidates would be a catalyst for share price appreciation, in our view. Valuation Summary We estimate the aggregate technical value of the programs to be higher than the current market price, but question where/how NVAX could access capital to realize that value." (5/9/2019)

Has Novavax been receiving favorable news coverage?

Media headlines about NVAX stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novavax earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Novavax.

Who are some of Novavax's key competitors?

What other stocks do shareholders of Novavax own?

Who are Novavax's key executives?

Novavax's management team includes the folowing people:
  • Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)
  • Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)
  • Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)
  • Dr. Gregory M. Glenn, Pres of R&D (Age 65)
  • Ms. Erika S. Trahan, Sr. Mang. of Investor & PR

Who are Novavax's major shareholders?

Novavax's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Creative Planning (0.39%), SG Americas Securities LLC (0.20%), Rhumbline Advisers (0.14%), Sargent Investment Group LLC (0.09%) and Tower Research Capital LLC TRC (0.03%). Company insiders that own Novavax stock include Gregory M Glenn, John A Herrmann III, John Trizzino, Rachel K King and Stanley C Erck. View Institutional Ownership Trends for Novavax.

Which institutional investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC and SG Americas Securities LLC. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III and John Trizzino. View Insider Buying and Selling for Novavax.

Which institutional investors are buying Novavax stock?

NVAX stock was bought by a variety of institutional investors in the last quarter, including Creative Planning, Tower Research Capital LLC TRC and Rhumbline Advisers. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, John Trizzino, Rachel K King and Stanley C Erck. View Insider Buying and Selling for Novavax.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $4.15.

How big of a company is Novavax?

Novavax has a market capitalization of $110.31 million and generates $34.29 million in revenue each year. The biopharmaceutical company earns $-184,750,000.00 in net income (profit) each year or ($10.00) on an earnings per share basis. Novavax employs 373 workers across the globe.View Additional Information About Novavax.

What is Novavax's official website?

The official website for Novavax is http://www.novavax.com/.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]


MarketBeat Community Rating for Novavax (NASDAQ NVAX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  624 (Vote Outperform)
Underperform Votes:  402 (Vote Underperform)
Total Votes:  1,026
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel